StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck noxafil (posaconazole, legacy) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, FY2024
177
Period ended Dec 31, 2024
Change on a year earlier
-16.9%
213 in FY2023
History
9 years
Since FY2016
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — Worldwide sales ($M) ($M)Year on yearSource
FY2024Dec 31, 2024177-16.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023213-10.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022238-8.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 2021259-21.3%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
FY2020Dec 31, 2020329-50.3%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 2019662-10.8%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2018Dec 31, 2018742+16.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 2017636+6.9%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 2016595–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up noxafil (posaconazole, legacy) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) — Worldwide sales ($M) ($M), annual FY2016–FY2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_noxafil

See every metric in the Merck KPI table. Data updated Oct 26, 2026.